Pharsight

Drugs that contain Glycopyrronium Tosylate

1. Qbrexza patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10548875 JOURNEY Glycopyrrolate salts
Feb, 2033

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10052267 JOURNEY Topical glycopyrrolate formulations
Oct, 2028

(4 years from now)

US8618160 JOURNEY Topical glycopyrrolate formulations
Dec, 2029

(5 years from now)

US9744105 JOURNEY Topical glycopyrrolate formulations
Jul, 2030

(6 years from now)

US10004717 JOURNEY Glycopyrrolate salts
Feb, 2033

(9 years from now)

US10543192 JOURNEY Glycopyrrolate salts
Feb, 2033

(9 years from now)

US8859610 JOURNEY Crystalline glycopyrrolate tosylate
Feb, 2033

(9 years from now)

US9259414 JOURNEY Glycopyrrolate salts
Feb, 2033

(9 years from now)

Market Authorisation Date: 28 June, 2018

Treatment: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older

Dosage: CLOTH;TOPICAL

How can I launch a generic of QBREXZA before it's drug patent expiration?
More Information on Dosage

QBREXZA family patents

Family Patents